Synergy of leptin/STAT3 with HER2 receptor induces tamoxifen resistance in breast cancer cells through regulation of apoptosis-related genes
- 25 December 2014
- journal article
- Published by Springer Nature in Cellular Oncology
- Vol. 38 (2) , 155-164
Abstract
Tamoxifen is a major treatment modality for estrogen receptor positive breast cancer, but the occurrence of resistance remains a problem. Recently, obesity-related leptin has been found to interfere with tamoxifen in breast cancer MCF-7 cells. In the present study we investigated the effect of leptin on three tamoxifen-treated breast cancer cell types (i.e., MDA-MB-231, MCF-7 and MCF-7/HER2). The effect of tamoxifen/leptin treatment was evaluated using a MTT cell viability assay. mRNA expression was assessed by real time PCR and protein expression by Western blotting. WWOX, Survivin and BCL2 gene promoter activities were evaluated by chromatin immunoprecipitation. Cell viability assays revealed that estrogen receptor negative MDA-MB-231 cells were resistant, that estrogen receptor positive MCF-7 cells were HER2 cells were relatively resistant to/HER2 cells were relatively resistant to tamoxifen, while leptin co-administration ‘rescued’ MCF-7 and, especially, MCF-7/HER2 cells from the anti-proliferative effect of tamoxifen. The cell lines also exhibited a different phosphorylation status of STAT3, a transcription factor that is activated by the obesity related leptin receptor b (Ob-Rb). Most importantly, chromatin immunoprecipitation assays revealed differential STAT3 binding to the anti-apoptotic BCL2 and pro-apoptotic WWOX gene promoters in MCF-7 and MCF-7/HER2 cells, leading to concomitant modifications of its mRNA/protein expression levels, thus providing a selective advantage to HER2 over-expressing MCF-7/HER2 cells after treatment with tamoxifen and tamoxifen plus leptin. Our study provides novel evidence indicating that synergy between the leptin/Ob-Rb/STAT3 signalling pathway and the HER2 receptor protects tamoxifen-treated HER2 over-expressing cells from the inhibitory effect of tamoxifen through differential regulation of apoptosis-related genes.Keywords
This publication has 73 references indexed in Scilit:
- ERM/Rho protein expression in ductal breast cancer: a 15 year follow-upCellular Oncology, 2013
- Benzyl isothiocyanate inhibits oncogenic actions of leptin in human breast cancer cells by suppressing activation of signal transducer and activator of transcription 3Carcinogenesis, 2010
- Leptin/HER2 crosstalk in breast cancer: in vitro study and preliminary in vivoanalysisBMC Cancer, 2008
- Molecular Approaches towards the Inhibition of the Signal Transducer and Activator of Transcription 3 (Stat3) ProteinChemMedChem, 2008
- Stat3 Promotes Metastatic Progression of Prostate CancerThe American Journal of Pathology, 2008
- Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifenBMC Genomics, 2008
- Persistent Activation of Stat3 Signaling Induces Survivin Gene Expression and Confers Resistance to Apoptosis in Human Breast Cancer CellsClinical Cancer Research, 2006
- Body size and breast cancer risk: Findings from the European prospective investigation into cancer and nutrition (EPIC)International Journal of Cancer, 2004
- Validating survivin as a cancer therapeutic targetNature Reviews Cancer, 2003
- Presence of Leptin in Breast Cell Lines and Breast TumorsBiochemical and Biophysical Research Communications, 1999